Lenvatinib is used to treat thyroid cancer. Lenvatinib is usually given after radioactive iodine has been tried without success.
Lenvatinib is used together with everolimus (Afinitor) to treat advanced kidney cancer when other medicines have not been effective.
Lenvatinib is used together with pembrolizumab (Keytruda) to treat a certain type of endometrial cancer (a type of uterine cancer) that has progressed and cannot be removed with surgery or radiation.
Lenvatinib is a tyrosine kinase inhibitor. It works by blocking the oxygen and nutrient supply to cancer cells due to which they stop growing.
Major & minor side effects for Lenvatinib
- Constipation
- Nosebleed
- Fast heartbeat
- Vomiting
- Coughing up blood
- Hair loss
- Bleeding gums
- Skin rash
- Heartburn or indigestion
- Yellow colored eyes or skin
- Stomach pain or tenderness
- Troubled breathing
- Loss of appetite
This medicine is not recommended for use in pregnant and breastfeeding women unless necessary.
This medicine should be used with caution in patients with kidney and liver diseases due to the increased risk of severe adverse effects.
This medicine should be used with extreme caution in patients suffering from stomach or intestine problems due to the increased risk of worsening of the patient's condition.
This medicine should be used with caution in patients with hypocalcemia (low blood calcium levels) due to the increased risk of severe adverse effects.
This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.
Use of this medicine may cause dizziness, visual disturbances, and tiredness.
This medicine should be used with extreme caution in patients who have or may develop prolongation of QT interval due to the increased risk of worsening of the patient's condition.
This medicine should be used with extreme caution in patients with a known risk of bleeding due to the increased risk of worsening of the patient's condition.
This medicine should be used with caution in patients with heart diseases due to the increased risk of worsening of the patient's condition.